SKU: D001  / 
    CAS Number: 23541-50-6

    Daunorubicin Hydrochloride

    $117.50 - $485.50

    Daunorubicin Hydrochloride (syn: Daunorubicin HCl) is a water soluble anthracycline antibiotic.  It is a chemotherapeutic agent produced by Streptomyces coeruleorubidus.  It acts as a polymerase inhibitor, and has been found to have anti-cancer properties.  

    Daunorubicin HCl is slightly soluble in water.

    This product is considered a dangerous good. Quantities above 1 g may be subject to additional shipping fees. Please contact us for specific questions.

    Mechanism of Action Daunorubicin acts as a polymerase inhibitor and demonstrates DNA intercalation activity which effectively inhibits cancer progress.
    Cancer Applications

    Daunorubicin HCl is a anti-neoplastic agent.  Commercially, it is approved by the FDA as a remission induction agent for acute myeloid leukemia research.  Specifically, it is for acute myelogenous, promyelocytic and erythroid leukemia.

    A novel bioactive peptide from pomegranate was found to exhibit anti-cancer activity. The peptide, PG2, had anti-cancer properties when studied in vitro with acute leukemia cells. A research team at Mahidol University in Thailand found that when they used Daunorubicin, it had a synergistic effect on its activity. (Charoensedtasin et al, 2024).

    Molecular Formula C27H29NO10 · HCl
    Solubility 1mg/mL in H2O: Clear and red or orange solution
    References

    Charoensedtasin K, Norkaew C, Naksawat M et al (2024)  Anticancer effects of pomegranate-derived peptide PG2 on CDK2 and miRNA-339-5p-mediated apoptosis via extracellular vesicles in acute leukemia. Sci Rep 14:27367

    Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA (1994)  Interference by Doxorubicin with DNA unwinding in MCF-7 breast tumor cells". Mol Pharmacol 45 (4):649–656

    Mizuno NS et al (1975)  Binding of daunomycin to DNA and the inhibition of RNA and DNA synthesis. Cancer Res. 35:1542-1546

    Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA (1967) Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia.  Cancer 20 (3):333–353